Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Chanan-Khan

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Blood|October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C Byrd, Peter Hillmen, Paolo Ghia, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
Mayo Clinic Proceedings|June 5, 2026
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026Sameer A Parikh, Paul J Hampel, Lindsey E Roeker, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic MalignancyJing Deng, Aneel Paulus, Douglas D Fang, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Oncotarget|April 21, 2017
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to deliveryAlan H Bryce, Jan B Egan, Mitesh J Borad, et al.
Med (New York, N.Y.)|October 18, 2025
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 studyMatthew S Davids, Asher Chanan-Khan, Sikander Ailawadhi, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Blood|October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C Byrd, Peter Hillmen, Paolo Ghia, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
Mayo Clinic Proceedings|June 5, 2026
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026Sameer A Parikh, Paul J Hampel, Lindsey E Roeker, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2017
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic MalignancyJing Deng, Aneel Paulus, Douglas D Fang, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Oncotarget|April 21, 2017
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to deliveryAlan H Bryce, Jan B Egan, Mitesh J Borad, et al.
Med (New York, N.Y.)|October 18, 2025
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 studyMatthew S Davids, Asher Chanan-Khan, Sikander Ailawadhi, et al.
Pageof 11